The General Practitioner-Pharmacist Collaboration (GPPC) study: A randomised controlled trial of clinical medication reviews in community pharmacy

International Journal of Pharmacy Practice

Volumn 19, Issue 2, 2011, Pages 94-105

  Bryant, Linda J M ^a   Coster, Gregor ^a   Gamble, Greg D ^a   McCormick, Ross N ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

barriers; community pharmacy services; Medication Appropriateness Index; medication reviews; pharmacists

Indexed keywords

ADULT; ARTICLE; EMOTION; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHARMACIST; PHARMACY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOCIAL STATUS;

AGED; AGED, 80 AND OVER; COMMUNITY PHARMACY SERVICES; COOPERATIVE BEHAVIOR; DRUG UTILIZATION REVIEW; FEMALE; FOLLOW-UP STUDIES; GENERAL PRACTITIONERS; HUMANS; INTERPROFESSIONAL RELATIONS; MALE; MIDDLE AGED; PHARMACISTS; PROFESSIONAL ROLE; QUALITY OF LIFE;

EID: 79952615158     PISSN: 09617671     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7174.2010.00079.x     Document Type: Article

References (51)

1. Johnson JA, Bootman JL,. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 1995; 155: 1949-1956.
2. White TJ, et al. Counting the costs of drug-related adverse events. Pharmacoeconomics 1999; 15: 445-458. (Pubitemid 29210948)
3. Ernst FR, Grizzle AJ,. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) 2001; 41: 192-199.
4. Holland R, et al. Systematic review of multidisciplinary interventions in heart failure. Heart 2005; 91: 899-906. (Pubitemid 40874078)
5. Shojania KG, et al. Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis. JAMA 2006; 296: 427-440. (Pubitemid 44127527)
6. Royal S, et al. Interventions in primary care to reduce medication related adverse events and hospital admissions: systematic review and meta analysis. Qual Saf Health Care 2006; 15: 23-31. (Pubitemid 43275522)
7. Chumney EC, Robinson L,. The effects of pharmacist interventions on patients with polypharmacy. Pharm Pract 2006; 4: 103-109. (Pubitemid 46061509)
8. Holland R, et al. Where now for pharmacist led medication review? J Epidemiol Community Health 2006; 60: 92-93. (Pubitemid 43131924)
9. Wermeille J, et al. Pharmaceutical care model for patients with type 2 diabetes: integration of the community pharmacist into the diabetes team-a pilot study. Pharm World Sci 2004; 26: 18-25. (Pubitemid 38250176)
10. Carter BL, et al. Extent of services provided by pharmacists in the Iowa Medicaid Pharmaceutical Case Management program. J Am Pharm Assoc 2003; 43: 24-33.
11. Chrischilles E, et al. Evaluation of the Iowa Medicaid Pharmaceutical Case Management Program. J Am Pharm Assoc (Wash) 2004; 44: 337-349.
12. Hepler CD, Strand LM,. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47: 533-543. (Pubitemid 20138134)
13. Hanlon J, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol 1992; 45: 1045-1051.
14. Medical Outcomes Trust. SF-36 Health Survey-Scoring Manual for English Language Adaptations: Australia/New Zealand, Canada, United Kingdom. Boston, MA: Medical Outcomes Trust, 1994.
15. Ministry of Health. Taking the Pulse. A 1996/97 Survey of Health Status. Wellington, New Zealand: Ministry of Health, 1999. (accessed 10 November 2010).
16. Schmader K, et al. Inappropriate prescribing and health outcomes in elderly veteran outpatients. Ann Pharmacother 1997; 31: 643-644.
17. Park JJ, et al. Comprehensive pharmaceutical care in the chain setting. J Am Pharm Assoc 1996; NS36: 443-451.
18. Shibley MC, Pugh CB,. Implementation of pharmaceutical care services for patients with hyperlipidemias by independent community pharmacy practitioners. Ann Pharmacother 1997; 31: 713-719. (Pubitemid 27242378)
19. Berringer R, et al. Outcomes of a community pharmacy-based diabetes monitoring program. J Am Pharm Assoc (Wash) 1999; 39: 791-797.
20. Berardo DH, et al. Community pharmacists' documentation of interventions on drug related problems of elderly patients. J Soc Admin Pharm 1994; 11: 182-192.
21. March G, et al. Developing and evaluating a model for pharmaceutical care in Australian community pharmacies. Int J Pharm Prac 1999; 7: 220-229. (Pubitemid 30088584)
22. Nathan A, et al. 'Brown bag' medication reviews as a means of optimizing patients' use of medication and of identifying potential clinical problems. Fam Pract 1999; 16: 278-282. (Pubitemid 29346911)
23. Bluml BM, et al. Pharmaceutical care services and results in project ImPACT: hyperlipidemia. J Am Pharm Assoc 2000; 40: 157-165.
24. Kassam R, et al. Pharmaceutical care research and education project: pharmacists' interventions. J Am Pharm Assoc 2001; 41: 401-410.
25. McLean W, et al. The BC community pharmacy asthma study: a study of clinical, economic and holistic outcomes influenced by an asthma care protocol provided by specially trained community pharmacists in British Columbia. Can Respir J 2003; 10: 195-202. (Pubitemid 36986739)
26. Sturgess I, et al. Community pharmacy based provision of pharmaceutical care to older patients. Pharm World Sci 2003; 25: 218-226. (Pubitemid 37254700)
27. Holland R, et al. Does pharmacist-led medication review help to reduce hospital admissions and deaths in older people? Asystematic review and meta-analysis. Br J Clin Pharmacol 2007; 65: 3003-3016.
28. Bernsten C, et al. Improving the well-being of elderly patients via community pharmacy-based provision of pharmaceutical care: a multicentre study in seven European countries. Drugs Aging 2001; 18: 63-77. (Pubitemid 32182133)
29. Sorensen L, et al. Medication reviews in the community: results of a randomized, controlled effectiveness trial. Br J Clin Pharmacol 2004; 58: 648-664. (Pubitemid 39665152)
30. Krska J, et al. Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age Ageing 2001; 30: 205-211. (Pubitemid 32684900)
31. Salter C, et al. 'I haven't even phoned my doctor yet.' The advice giving role of the pharmacist during consultaions for medication review with patients aged 80 or more: qualitative discourse analysis. BMJ 2007; 334: 1101-1104. (Pubitemid 46867131)
32. Tsuyuki RT, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 2002; 162: 1149-1155. (Pubitemid 34522403)
33. Armour CL, et al. Implementation and evaluation of Australian pharmacists' diabetes care services. J Am Pharm Assoc (Wash) 2004; 44: 455-466.
34. Gilbert AL, et al. Collaborative medication management services: improving patient care. Med J Aust 2002; 177: 189-192. (Pubitemid 35021429)
35. Sellors J, et al. A randomized controlled trial of a pharmacist consultation program for family physicians and their elderly patients. CMAJ 2003; 169: 17-22. (Pubitemid 36898071)
36. Isetts BJ, et al. Quality assessment of a collaborative approach for decreasing drug-related morbidity and achieving therapeutic goals. Arch Intern Med 2003; 163: 1813-1820. (Pubitemid 36960929)
37. Zermansky AG, et al. Clinical medication review by a pharmacist of patients on repeat prescriptions in general practice: a randomised controlled trial. Health Technol Assess 2002; 6: 1-86.
38. Bond C,. The MEDMAN study: a randomized controlled trial of communmity pharmacy-led medicines management for patients with coronary heart disease. Fam Prac 2007; 24: 189-200. (Pubitemid 47079267)
39. Holland R, et al. Effectives of visits from community pharmacists for patients with heart failure: HeartMed randomised controlled trial. BMJ 2007; 334: 1098-1101. (Pubitemid 46867130)
40. Holland R, et al. Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial. BMJ 2005; 330: 293.
41. Strand LM, et al. The impact of pharmaceutical care practice on the practitioner and the patient in the ambulatory practice setting: twenty-five years of experience. Curr Pharm Design 2004; 10: 3987-4001. (Pubitemid 39591913)
42. Tsuyuki RT, et al. Effect of community pharmacist intervention on cholesterol levels in patients at high risk of cardiovascular events: the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus). Am J Med 2004; 116: 130-133. (Pubitemid 38056665)
43. McLean WM, MacKeigan LD,. When does pharmaceutical care impact health outcomes? A comparison of community pharmacy-based studies of pharmaceutical care for patients with asthma. Ann Pharmacother 2005; 39: 625-631. (Pubitemid 40396614)
44. Herborg H, et al. Improving drug therapy for patients with asthma-part 1: patient outcomes. J Am Pharm Assoc 2001; 41: 539-550.
45. Emmerton L, Kheir N,. Asthma management by New Zealand pharmacists: a pharmaceutical care demonstration project. J Clin Pharm Ther 2003; 28: 395-402. (Pubitemid 37352449)
46. Saini B, et al. Development, implementation, and evaluation of a community pharmacy-based asthma care model. Ann Pharmacother 2004; 38: 1954-1960. (Pubitemid 39425733)
47. Lenaghan E, et al. Home-based medication review in a high risk elderly population in primary care-the POLYMED randomised controlled trial. Age Ageing 2007; 36: 292-297. (Pubitemid 47072323)
48. RESPECT Trial Team. Effectiveness of shared pharmaceutical care for older patients: RESPECT trial findings. Br J Gen Pract 2010; 60: 10-19.
49. Zermansky AG, et al. Randomised controlled trial of clinical medication review by a pharmacist of elderly patients receiving repeat prescriptions in general practice. BMJ 2001; 323: 1340-1343. (Pubitemid 33152213)
50. Malone DC, et al. An economic analysis of a randomized, controlled, multicenter study of clinical pharmacist interventions for high-risk veterans: the IMPROVE study. Impact of Managed Pharmaceutical Care Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy 2000; 20: 1149-1158.
51. Merenich J, et al. Mortality reduction benefits in a comprehensive cardiac care program for patients with occlusive coronary artery disease. Pharmacotherapy 2007; 27: 1370-1378. (Pubitemid 47530443)